Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Total Liabilities (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Total Liabilities for 6 consecutive years, with $105.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 18.81% to $105.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $105.7 million, a 18.81% decrease, with the full-year FY2025 number at $105.7 million, down 18.81% from a year prior.
  • Total Liabilities was $105.7 million for Q4 2025 at TScan Therapeutics, down from $118.2 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $130.1 million in Q4 2024 to a low of $20.8 million in Q2 2022.
  • A 5-year average of $87.5 million and a median of $111.8 million in 2024 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: crashed 54.91% in 2022, then soared 508.37% in 2023.
  • TScan Therapeutics' Total Liabilities stood at $27.3 million in 2021, then surged by 264.66% to $99.7 million in 2022, then grew by 21.7% to $121.3 million in 2023, then increased by 7.31% to $130.1 million in 2024, then fell by 18.81% to $105.7 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Total Liabilities are $105.7 million (Q4 2025), $118.2 million (Q3 2025), and $121.8 million (Q2 2025).